NASDAQ: GBIOGeneration Bio Co Stock
$1.30+0.02 (+1.56%)
Updated Dec 6, 2024
GBIO Price
$1.30
Fair Value Price
-$0.06
Market Cap
$86.83M
52 Week Low
$1.24
52 Week High
$4.65
P/E
-0.59x
P/B
0.83x
P/S
8.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.58M
Earnings
-$145.47M
Gross Margin
100%
Operating Margin
-782.87%
Profit Margin
-782.9%
Debt to Equity
1.38
Operating Cash Flow
-$98M
Beta
1.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GBIO Overview
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GBIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Value
C
Growth
C
Momentum
B
Sentiment
F
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GBIO
Ranked#143 of 554
Ranked#143 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important GBIO news, forecast changes, insider trades & much more!
GBIO News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GBIO ($1.30) is overvalued by 2,251.47% relative to our estimate of its Fair Value price of -$0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GBIO ($1.30) is not significantly undervalued (2,251.47%) relative to our estimate of its Fair Value price of -$0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GBIO due diligence checks available for Premium users.
Valuation
GBIO fair value
Fair Value of GBIO stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
-$0.06
Undervalued by
2,251.47%
GBIO ($1.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GBIO ($1.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GBIO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.59x
Industry
-105.55x
Market
29.86x
GBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.83x
Industry
5.68x
GBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GBIO's financial health
Profit margin
Revenue
$7.6M
Net Income
-$15.3M
Profit Margin
-202.7%
GBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$248.8M
Liabilities
$144.3M
Debt to equity
1.38
GBIO's short-term assets ($191.25M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GBIO's short-term assets ($191.25M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.5M
Investing
$12.7M
Financing
-$3.0k
GBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GBIO vs Biotech Stocks
Generation Bio Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.